Article
Pharmacology & Pharmacy
Yakun Li, Bingyang Xu, Jun Yang, Lu Wang, Xiaosheng Tan, Xiaofan Hu, Lingjuan Sun, Song Chen, Lan Zhu, Xiaoping Chen, Gang Chen
Summary: Liraglutide exerts protective effects against renal ischemia-reperfusion injury by inhibiting HMGB1 nuclear-cytoplasmic translocation and release, partially dependent on GLP-1R. This demonstrates its therapeutic potential in the prevention and treatment of organ IRI.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Alex Gallinat, Guiomar Mendieta, Gemma Vilahur, Teresa Padro, Lina Badimon
Summary: Cardiovascular diseases, especially acute myocardial infarction (MI), are major causes of death worldwide. DJ-1 protein has been found to play a crucial role in cardioprotection, and systemic administration of recombinant DJ-1 has been shown to reduce infarct size, leukocyte infiltration, apoptosis, and oxidative stress in a mouse model of MI. These effects may be mediated by G-protein-coupled receptor signaling and modulation of immune response. This study provides the first evidence for the extracellular activity of DJ-1 in regulating cardiac injury in vivo.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Zhuolun Song, Hui Han, Xiaodong Ge, Sukanta Das, Romain Desert, Dipti Athavale, Wei Chen, Sai Santosh Babu Komakula, Daniel Lantvit, Natalia Nieto
Summary: This study investigated the protective role of intracellular neutrophil-derived HMGB1 in early allograft dysfunction after liver transplantation. The results showed that the absence of Hmgb1 in recipient myeloid cells exacerbated graft injury. Therefore, intracellular HMGB1 plays an important role in protecting against early graft injury after liver transplantation.
Article
Biochemistry & Molecular Biology
Rolf Schreckenberg, Annemarie Wolf, Tamara Szabados, Kamilla Gomori, Istvan Adorjan Szabo, Gergely Agoston, Gabor Brenner, Peter Bencsik, Peter Ferdinandy, Rainer Schulz, Klaus-Dieter Schlueter
Summary: Hypoxia upregulates PCSK9 in the heart, which affects myocyte function. Genetic deletion of PCSK9 or antagonism of circulating PCSK9 reduces reperfusion injury. A high-fat diet decreases survival rate during reperfusion, likely due to increased MMP9 activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Chao Ren, Ren-qi Yao, Li-xue Wang, Jun-cong Li, Kun-wei Chen, Yao Wu, Ning Dong, Yong-wen Feng, Yong-ming Yao
Summary: This study found that HMGB1 plays a critical role in dysregulating immune response in sepsis, with the relationship between cerebral HMGB1 and splenic DC dysfunction being dependent on cholinergic system activity. The findings shed light on the mechanisms of immune dysfunction in sepsis and the potential therapeutic targets involving HMGB1 and cholinergic pathways.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Rebecca A. Sosa, Allyson Q. Terry, Fady M. Kaldas, Yi-Ping Jin, Maura Rossetti, Takahiro Ito, Fang Li, Richard S. Ahn, Bita V. Naini, Victoria M. Groysberg, Ying Zheng, Antony Aziz, Jessica Nevarez-Mejia, Ali Zarrinpar, Ronald W. Busuttil, David W. Gjertson, Jerzy W. Kupiec-Weglinski, Elaine F. Reed
Summary: The study identified disulfide-HMGB1 as a mechanistic biomarker and therapeutic target for minimizing sterile inflammation during human liver ischemia-reperfusion injury.
Article
Chemistry, Medicinal
Verena Peek, Lois M. Harden, Jelena Damm, Ferial Aslani, Stephan Leisengang, Joachim Roth, Ruediger Gerstberger, Marita Meurer, Maren von Koeckritz-Blickwede, Sabine Schulz, Bernhard Spengler, Christoph Rummel
Summary: This study revealed the mechanisms of HMGB1 action in the brain during rat sepsis, finding that HMGB1 enhances brain inflammatory responses and is associated with sustained sepsis symptoms.
Article
Biochemistry & Molecular Biology
Vicente Castrejon-Tellez, Leonardo del Valle-Mondragon, Israel Perez-Torres, Veronica Guarner-Lans, Gustavo Pastelin-Hernandez, Angelica Ruiz-Ramirez, Julieta Anabell Diaz-Juarez, Elvira Varela-Lopez, Victor Hugo Oidor-Chan, Alvaro Vargas-Gonzalez, Raul Martinez-Memije, Pedro Flores-Chavez, Bruno Leon-Ruiz, Sergio Arriaga-Carrillo, Juan Carlos Torres-Narvaez
Summary: TRPV1 activation regulates the NO pathway to counteract myocardial injury caused by ischemia-reperfusion.
Article
Cell Biology
Annie Turkieh, Yara El Masri, Florence Pinet, Emilie Dubois-Deruy
Summary: Mitophagy plays a crucial role in maintaining cardiac homeostasis by selectively eliminating dysfunctional mitochondria. It is mainly regulated by the PINK1/parkin pathway and also by the FUNDC1, BNIP3, and BNIP3L/NIX pathways. Dysregulated mitophagy is associated with cardiac dysfunction, while moderate mitophagy has a cardioprotective effect.
Article
Immunology
William A. Banks, Kim M. Hansen, Michelle A. Erickson, Fulton T. Crews
Summary: High-mobility group box 1 (HMGB1) is a protein that regulates transcription in the cell nucleus and activates the innate immune system. It can cross the blood-brain barrier (BBB) and affect neuroimmune signaling in the brain and periphery. In this study, the ability of radioactively labeled HMGB1 to cross the BBB was examined. The results showed that HMGB1 could bidirectionally cross the BBB and its transport rates were enhanced by inflammation. This finding suggests that HMGB1 levels have an impact on neuroimmune signaling in various conditions.
BRAIN BEHAVIOR AND IMMUNITY
(2023)
Review
Cell Biology
Sarah Saxena, Veronique Kruys, Raf De Jongh, Joseph Vamecq, Mervyn Maze
Summary: Aseptic surgical trauma induces the release of HMGB1, triggering the immune response and resulting in postoperative cognitive decline.
Review
Cell Biology
Bram DeWulf, Laurens Minsart, Franck Verdonk, Veronique Kruys, Michael Piagnerelli, Mervyn Maze, Sarah Saxena
Summary: Targeting HMGB1 can be a strategy to reduce sepsis-induced encephalopathy and complement non-pharmacological interventions.
Article
Nutrition & Dietetics
Laura Kate Gadanec, Ulf Andersson, Vasso Apostolopoulos, Anthony Zulli
Summary: High levels of HMGB-1 have been found in patients with Hyperhomocysteinemia (HHcy), which worsens cardiovascular outcomes. Targeting HMGB-1 may be a potential therapy for improving HHcy-induced cardiovascular pathologies.
Article
Biochemistry & Molecular Biology
Takaaki Totoki, Takashi Ito, Shingo Yamada, Goichi Honda, Tsuyoshi Hattori, Ikuro Maruyama
Summary: In this study, a monoclonal antibody specific to desHMGB1 was obtained and used to detect desHMGB1 through ELISA. The results showed a significant increase in plasma desHMGB1 levels in septic mice treated with rTM. This suggests that using the novel monoclonal antibody for ELISA may aid in the in-depth analysis of HMGB1-induced pathogenicity and rTM therapeutic efficiency.
MOLECULAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Kazuki Hatayama, Ray H. Chen, Jordan Hanson, Kiyoshi Teshigawara, Joseph Qiu, Andre Santoso, Clemence Disdier, Sakura Nakada, Xiaodi Chen, Masahiro Nishibori, Yow-Pin Lim, Barbara S. Stonestreet
Summary: The study confirmed specific binding characteristics between IAIPs and HMGB1 in vitro and demonstrated their co-localization in neonatal rats exposed to HI brain injury, suggesting a potential anti-inflammatory effect. The results indicate that HMGB1 could be a target of IAIPs, showing promise for future therapeutic interventions in neuroinflammation.